BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31134297)

  • 1. Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.
    Leick KM; Pinczewski J; Mauldin IS; Young SJ; Deacon DH; Woods AN; Bosenberg MW; Engelhard VH; Slingluff CL
    Cancer Immunol Immunother; 2019 Jul; 68(7):1121-1132. PubMed ID: 31134297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
    Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockout of MDA-9/Syntenin (SDCBP) expression in the microenvironment dampens tumor-supporting inflammation and inhibits melanoma metastasis.
    Das SK; Guo C; Pradhan AK; Bhoopathi P; Talukdar S; Shen XN; Emdad L; Subler MA; Windle JJ; Sarkar D; Wang XY; Fisher PB
    Oncotarget; 2016 Jul; 7(30):46848-46861. PubMed ID: 27341128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
    Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
    J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.
    Erdag G; Schaefer JT; Smolkin ME; Deacon DH; Shea SM; Dengel LT; Patterson JW; Slingluff CL
    Cancer Res; 2012 Mar; 72(5):1070-80. PubMed ID: 22266112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.
    Damsky WE; Curley DP; Santhanakrishnan M; Rosenbaum LE; Platt JT; Gould Rothberg BE; Taketo MM; Dankort D; Rimm DL; McMahon M; Bosenberg M
    Cancer Cell; 2011 Dec; 20(6):741-54. PubMed ID: 22172720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in Pten
    Deken MA; Song JY; Gadiot J; Bins AD; Kroon P; Verbrugge I; Blank CU
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
    Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
    Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BRAFV600E in an inducible murine model of melanoma.
    Hooijkaas AI; Gadiot J; van der Valk M; Mooi WJ; Blank CU
    Am J Pathol; 2012 Sep; 181(3):785-94. PubMed ID: 22796458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents.
    Zaidi S; Blanchard M; Shim K; Ilett E; Rajani K; Parrish C; Boisgerault N; Kottke T; Thompson J; Celis E; Pulido J; Selby P; Pandha H; Melcher A; Harrington K; Vile R
    Mol Ther; 2015 May; 23(5):845-856. PubMed ID: 25544599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
    Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
    J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
    DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
    J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma.
    Liu Q; Zhu H; Liu Y; Musetti S; Huang L
    Cancer Immunol Immunother; 2018 Feb; 67(2):299-310. PubMed ID: 29094184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
    Tormo D; Ferrer A; Bosch P; Gaffal E; Basner-Tschakarjan E; Wenzel J; Tüting T
    Cancer Res; 2006 May; 66(10):5427-35. PubMed ID: 16707471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.
    Lugade AA; Moran JP; Gerber SA; Rose RC; Frelinger JG; Lord EM
    J Immunol; 2005 Jun; 174(12):7516-23. PubMed ID: 15944250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis.
    Leick KM; Rodriguez AB; Melssen MM; Benamar M; Lindsay RS; Eki R; Du KP; Parlak M; Abbas T; Engelhard VH; Slingluff CL
    Ann Surg; 2019 Oct; 270(4):712-722. PubMed ID: 31425296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphatic dysfunction attenuates tumor immunity through impaired antigen presentation.
    Kimura T; Sugaya M; Oka T; Blauvelt A; Okochi H; Sato S
    Oncotarget; 2015 Jul; 6(20):18081-93. PubMed ID: 26098776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics.
    Lund AW; Duraes FV; Hirosue S; Raghavan VR; Nembrini C; Thomas SN; Issa A; Hugues S; Swartz MA
    Cell Rep; 2012 Mar; 1(3):191-9. PubMed ID: 22832193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
    Dabrosin N; Sloth Juul K; Bæhr Georgsen J; Andrup S; Schmidt H; Steiniche T; Heide Øllegaard T; Bønnelykke Behrndtz L
    Melanoma Res; 2019 Feb; 29(1):30-37. PubMed ID: 30299387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.